<DOC>
	<DOCNO>NCT00646724</DOCNO>
	<brief_summary>The study evaluate safety efficacy Cotransplantation Islet Mesenchymal Stem Cell Type 1 Diabetic Patients . The researcher hypothesize additional Mesenchymal Stem Cell infusion benefit promise clinical islet transplantation follow mechanism : protection islet inflammatory damage , immunological modulation , engraftment promotion , thus decrease eliminate need exogenous insulin improve Î²-cell function .</brief_summary>
	<brief_title>Cotransplantation Islet Mesenchymal Stem Cell Type 1 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Male female patient age 18 60 year age Ability provide write informed consent Manifest sign symptom severe enough incapacitating Patients poor diabetes control ( HbA1c &gt; 7 % &lt; 12 % ) Progressive diabetic complication age &lt; 18 year &gt; 60 year diabetic history &lt; 5 year BMI &gt; 27 body weight &gt; 80 kg exogenous insulin requirement &gt; 1 unit/kg/day severe anemia ( male &lt; 8 g/dl , female &lt; 7 g/dl ) low white blood cell count ( &lt; 3000/dl ) liver dysfunction Active infection include hepatitis B , hepatitis C , HIV , TB panel reactive antibody &gt; 20 % Any medical condition , opinion investigator , interfere safe completion trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Islets Langerhans Transplantation</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
</DOC>